Trial intelligence / Profile preview

Expanded Access Program of Selpercatinib for RET-Activated Solid Tumors in Japan

jRCT2080225226Completed

Sponsor

Loxo Oncology

Start

Jun 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules